COBTH in the News

Boston Children's Hospital offering Pfizer COVID-19 vaccine to all patients 12 and older

Boston Children's Hospital offering Pfizer COVID-19 vaccine to all patients 12 and older

WCVB

WCVB

Tuesday's announcement from the hospital comes one day after the U.S. Food and Drug Administration authorized Pfizer's vaccine for emergency use in children ages 12 to 15.

Meet A Group Of Volunteers Bringing The Vaccine Into Boston Communities With Low Rates

Meet A Group Of Volunteers Bringing The Vaccine Into Boston Communities With Low Rates

May 12, 2021

WBUR

Dr. Alister Martin is an emergency room physician at Massachusetts General Hospital, and a founder of the GOTVax program.

How Hospitals Can Help Patients and the Planet

How Hospitals Can Help Patients and the Planet

May 12, 2021

New York Times

Since 2012, Boston Medical Center has lowered its energy use by nearly 40 percent and reduced its greenhouse gas emissions from all sources of energy by 90 percent while caring for more patients.

Hale family donates $50M to Dana-Farber for pancreatic cancer research

Hale family donates $50M to Dana-Farber for pancreatic cancer research

May 12, 2021

Boston Business Journal

The CEO and family of Quincy-based Granite Telecommunications has given $50 million to Dana-Farber Cancer Institute in support of pancreatic cancer research.

Sleep Disorders Cost Nearly $95 Billion Per Year

Sleep Disorders Cost Nearly $95 Billion Per Year

May 11, 2021

WebMD

"Our estimates are likely low, considering we know there are a large number of patients not yet diagnosed with a disorder like sleep apnea, restless legs syndrome and insomnia," said researcher Dr. Neil Bhattacharyya, an ear, nose and throat doctor at Massachusetts Eye and Ear Hospital in Boston.

'Game-changer' cancer drug celebrates 20 years. Gleevec turned a death sentence into a chronic disease for many.

'Game-changer' cancer drug celebrates 20 years. Gleevec turned a death sentence into a chronic disease for many.

May 10, 2021

Detroit Free Press

The fact that it's a long-term therapy means drug companies can make a lot of money, even on relatively rare diseases, said Dr. George Demetri, director of the Sarcoma Center at Dana-Farber Cancer Institute in Boston.